{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T03:31:14Z","timestamp":1780803074547,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Melior Pharmaceuticals"},{"name":"Bukwang Pharmaceutical Co. Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jdiacomp.2020.107555","type":"journal-article","created":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T23:17:05Z","timestamp":1580599025000},"page":"107555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus"],"prefix":"10.1016","volume":"34","author":[{"given":"Moon-Kyu","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Gon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Youl","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Frias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Hee","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Greenway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2020.107555_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/2468-8827.184853","article-title":"WHO global report on diabetes: a summary","volume":"1","author":"Roglic","year":"2016","journal-title":"International Journal of Noncommunicable Diseases"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-131-4-199908170-00008","article-title":"Pharmacologic therapy for type 2 diabetes mellitus","volume":"131","author":"DeFronzo","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature."},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.112.192187","article-title":"The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes","volume":"342","author":"Ochman","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/jpet.112.192096","article-title":"MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo","volume":"342","author":"Saporito","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0030","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/BF03401827","article-title":"The molecular mechanism of the insulin-mimetic\/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl","volume":"6","author":"Muller","year":"2000","journal-title":"Mol Med"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0035","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1128\/MCB.21.14.4553-4567.2001","article-title":"Redistribution of glycolipid raft domain components induces insulin-mimetic signaling in rat adipocytes","volume":"21","author":"Muller","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0040","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bcp.2004.11.014","article-title":"Regulation of lipid raft proteins by glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C in rat adipocytes","volume":"69","author":"Muller","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0045","first-page":"744","article-title":"Pancreatic beta-cell responsiveness during meal tolerance test: model assessment in normal subjects and subjects with newly diagnosed noninsulin-dependent diabetes mellitus","volume":"83","author":"Hovorka","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12933-014-0169-9","article-title":"Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study","volume":"14","author":"Nishimura","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007611-200295010-00014","article-title":"Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes","volume":"95","author":"Dezii","year":"2002","journal-title":"South Med J"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0060","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079907X188152","article-title":"Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes","volume":"23","author":"Hanefeld","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0065","unstructured":"Greenway F, Guzman F, Tamayo RA, et al. Clinical POC for an anti-diabetic agent with a novel mechanism for reducing insulin resistance. 2016."},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00125-008-0930-2","article-title":"Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin","volume":"51","author":"Aston-Mourney","year":"2008","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0075","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.bcp.2004.01.016","article-title":"Beta-cell toxicity of ATP-sensitive K+ channel-blocking insulin secretagogues","volume":"67","author":"Rustenbeck","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tips.2016.01.007","article-title":"Repurposing drugs to target the diabetes epidemic","volume":"37","author":"Turner","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14740338.2013.752813","article-title":"A review of the efficacy and safety of oral antidiabetic drugs","volume":"12","author":"Stein","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jdiacomp.2020.107555_bb0090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","article-title":"Oral antihyperglycemic therapy for type 2 diabetes: scientific review","volume":"287","author":"Inzucchi","year":"2002","journal-title":"JAMA."}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872719309286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872719309286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:10:37Z","timestamp":1761005437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872719309286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1056872719309286"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107555","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107555"}}